Calidi Biotherapeutics Inc (CLDI)
0.2464
+0.01
(+5.48%)
USD |
NYAM |
May 16, 16:00
0.2464
0.00 (0.00%)
After-Hours: 20:00
Calidi Biotherapeutics Research and Development Expense (Quarterly): 3.958M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.958M |
| September 30, 2023 | 3.251M |
| December 31, 2022 | 2.263M |
| Date | Value |
|---|---|
| September 30, 2022 | 1.945M |
| December 31, 2021 | 1.375M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.375M
Minimum
Dec 2021
3.958M
Maximum
Dec 2023
2.558M
Average
2.263M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Minerva Neurosciences Inc | 4.167M |
| Viking Therapeutics Inc | 24.10M |
| CytomX Therapeutics Inc | 22.05M |
| Genprex Inc | 3.713M |
| Janux Therapeutics Inc | 14.07M |